References of Platinum,[rel-(1R,2R)-1,2-cyclobutanedimethanamine-kN,kN'][(2S)-2-(hydroxy-kO)propanoato(2-)-kO]-, (SP-4-3)- (9CI)
Title: Lobaplatin
CAS Registry Number: 135558-11-1
CAS Name: (
SP-4-3)-[
rel-(1
R,2
R)-1,2-Cyclobutanedimethanamine-k
N,k
N¢][(2
S)-2-(hydroxy-k
O)propanoato(2-)-k
O]platinum
Synonyms: cis-[
trans-1,2-cyclobutanebis(methylamine)][(
S)-lactato-
O1,
O2]platinum
Manufacturers' Codes: D-19466
Molecular Formula: C9H18N2O3Pt
Molecular Weight: 397.33
Percent Composition: C 27.21%, H 4.57%, N 7.05%, O 12.08%, Pt 49.10%
Literature References: Water-soluble platinum compound; mixture of two
trans diastereoisomers. Prepn: W. Schumacher
et al., EP 324154;
eidem, US 5023335 (1989, 1991 both to ASTA Pharma); and pharmacology: R. Voegeli
et al., J. Cancer Res. Clin. Oncol. 116, 439 (1990). HPLC determn of diastereoisomers in plasma: J. Welink
et al., J. Chromatogr. B 675, 107 (1996). Clinical evaluation: M. Degardin
et al., Invest. New Drugs 13, 253 (1995); and pharmacokinetics: J. A. Gietema
et al., Br. J. Cancer 71, 1302 (1995). Evaluation in canine osteosarcoma: J. Kirpensteijn
et al., Anticancer Res. 22, 2765 (2002). Review of clinical development: M. J. McKeage,
Expert Opin. Invest. Drugs 10, 119-128 (2001).
Properties: Crystals from diethyl ether, mp 220° (dec). Sol in water. LD50 i.p. in mice: 46 mg/kg (Voegeli).
Melting point: mp 220° (dec)
Toxicity data: LD50 i.p. in mice: 46 mg/kg (Voegeli)
Therap-Cat: Antineoplastic.
Therap-Cat-Vet: Antineoplastic.
Keywords: Antineoplastic; Platinum Complexes.